Open company graph database — free web & API
Login

DAIICHI SANKYO EUROPE GmbH

大塚三薬ヨーロッパ有限会社Alias
Ticker
—
Listed market
—
Country
Germany
Employees (non-consolidated)
—
Related companies
15
§01

Basic information

BASIC
Head office
Zielstattstr. 48, 81379 Munich, Germany
Chief executive
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

16
Adverse Event ReportingDownload CenterExpanded Access to Investigational ProductsDaiichi Sankyo WebsitesContactFind UsCountriesOncology adverse event reportingDownload centerCompany websitesCustomer contact servicesFind us servicesExpanded access to investigational productsOncology drug development and marketingAdverse event reporting servicesHealthcare information services
§04

Related companies

15 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
DAIICHI SANKYO (SCHWEIZ) AG
Group
DAIICHI SANKYO Netherlands B.V.
Group
DAIICHI SANKYO AUSTRIA GmbH
Group
DAIICHI SANKYO BELGIUM N.V.-S.A.
Group
Daiichi Sankyo Germany GmbH
Group
DAIICHI SANKYO FRANCE SAS
Group
DAIICHI SANKYO Greece Single Member S.A.
Group
DAIICHI SANKYO IRELAND LIMITED
Group
DAIICHI SANKYO ITALIA S.p.A.
Group
DAIICHI SANKYO Pharma Canada Limited
Group
DAIICHI SANKYO PORTUGAL, UNIPESSOAL Lda.
Group
DAIICHI SANKYO ESPAÑA, S.A.U.
Group
DAIICHI SANKYO UK LTD.
Group
DAIICHI SANKYO Pharmaceutical, Trading Ltd. Co.
Group
Daiichi Sankyo Nordics ApS
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

32 EVENTS

First isolation of adrenaline by Dr. Jokichi Takamine, the first president of Sankyo ShotenSources

Our roots in Europe can be traced back to Luitpold-Werk, a pharmaceutical company founded on 22 January 1910 in Munich, Germany.Sources

The company established its first factory on Munich’s Zielstattstrasse in 1928, with over 100 employees, producing primarily digestive enzymes shipped to about 50 countries.Sources

By 1942, the number of employees had risen to about 300, despite difficulties in obtaining raw materials and limited export options.Sources

In 1943, Munich was bombed, destroying the facilities on Zielstattstrasse. Business activities continued with departments moving to temporary offices and laboratories across the city, leading to the decision to build new production facilities in Pfaffenhofen.Sources

After World War II, business activities resumed within months. In the 1950s and 1960s, new offices in Munich and production facilities in Pfaffenhofen were established.Sources

From 1962, Luitpold-Werk increased its international presence by establishing affiliates in Brazil, Spain, Switzerland, and Italy, and built a new production site in Altkirch, France.Sources

Discovery of the first HMG-CoA reductase inhibitor by Sankyo - origin of the statin classSources

Between 1981 and 1986, subsidiaries were established in the United States, Portugal, and the United Kingdom, expanding Luitpold’s international presence.Sources

Daiichi discovers levofloxacin, the first third-generation quinoloneSources

Sankyo established two international subsidiaries in New York and Düsseldorf, and Luitpold founded an affiliate in Austria.Sources

Sankyo acquired Luitpold-Werk, gaining a presence in Europe and Latin America.Sources

Luitpold-Werk was renamed Sankyo Pharma.Sources

Launch of olmesartan, an angiotensin II receptor blockerSources

Sankyo launched olmesartan (Olmetec®/Benicar®) and acquired Paris-based Laboratories Fornet to expand in Europe.Sources

Sankyo and Daiichi established a joint holding company in Japan named Daiichi Sankyo Company, Limited, followed by the European merger in 2006.Sources

Daiichi Sankyo Europe was founded as the new European headquarters in Munich, integrating business activities in the UK and Germany.Sources

Further investments were made in the German production site in Pfaffenhofen, with new facilities opened.Sources

U3 Pharma was acquired to strengthen oncology pipeline, and rights for Evista® (raloxifene) were acquired from Eli Lilly.Sources

Efient® (prasugrel), an oral antiplatelet agent, was launched in several European countries.Sources

New affiliates opened in Ireland and Turkey; sales force capacity increased by taking over representatives from Merck Serono, growing European employees to nearly 2,500.Sources

Following the earthquake and tsunami in Japan, support was provided to colleagues, including taking over drug production in Pfaffenhofen, and launching 'Daiichi Sankyo Children Aid' for affected children.Sources

Presented Phase III results of the Hokusai-VTE study for edoxaban at ESC congress, and announced results from ENGAGE AF-TIMI 48 study.Sources

Daiichi Sankyo acquired Ambit Biosciences; a new Pharmaceutical Development building was inaugurated at Pfaffenhofen, providing facilities for 100 employees.Sources

Launch of edoxaban, a non-vitamin K antagonist oral anticoagulant (NOAC) and direct factor Xa inhibitorSources

Edoxaban was approved in the European Union and introduced in the first markets.Sources

A licensing agreement was concluded with Esperion for marketing oral bempedoic acid and its fixed-dose combination.Sources

European Commission approval and first launch of bempedoic acid in Europe. Bempedoic acid and its fixed-dose combination with ezetimibe is approved for use in adults with primary hypercholesterolemia or mixed dyslipidemia in EuropeSources

Bempedoic acid and its fixed-dose combination with ezetimibe were approved in the EU in April 2020, later introduced into the market in late 2020, with relief efforts launched during COVID-19.Sources

Daiichi Sankyo’s first oncological product received conditional approval in Europe in January 2021.Sources

In April 2023, Daiichi Sankyo opened a new Canadian affiliate as part of the European region.Sources

Further milestones of around 1 billion euros have been implemented at the Pfaffenhofen site to develop it into an international innovation centre for oncology.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑